Lymphocytes, Interleukin 6 and D-dimer Cannot Predict Clinical Outcome in Coronavirus Cancer Patients: LyNC1.20 Study

Abstract

Background/Aim: Knowledge of Coronavirus 19 (COVID19) pathogenetic mechanisms is necessary to provide new treatment strategies. This study aims to assess how oncological disease impacts on the clinical course of COVID-19 patients. Patients and Methods: From 1 st March to 30 th April 2020, 96 COVID-19 patients were classified according to clinical outcome as severe (n=67) and moderate (n=29). Demographic data, medical history, admission lymphocytes, procalcitonin (PCT), were collected. Results: A statistically significant association was found between hypertension (p=0.007) and three or more comorbidities with severe outcomes (p=0.034). No statistical differences were found between the severe and moderate groups with regards to the rate of patients with past oncological history. However, no patient allocated in the moderate group had received oncological treatment within 12 months. Higher values of CRP, IL-6, D-Dimer and lower values of lymphocytes were reported in the severe group (p=0.0007, p=0.00386, p=0.041, and p=0.007, respectively). Using binary logistic regression, higher values of CRP (OR=8.861; p=0.012) and PCT were associated with a higher risk of severe outcome (OR=21.075; p=0.008). Within the oncological population, D-Dimer and IL-6 did not confirm their prognostic significance as in the general population (p>0.05). Conclusion: Specific prognostic factors for oncological patients should be designed for COVID-19 clinical practice.The Coronavirus-19 (COVID-19) pandemic represents a global challenge due to the rapid spread and poor prognosis, with a fatality rate of 6.2% and more than 5 million people infected worldwide (1). COVID-19 has strongly impacted all medical science fields and several physicians are currently reorganizing their clinical practice in order to provide the best treatment and reduce the risk of cross contamination (2-4). Based on the most recent flu pandemic, the Center for Infectious Disease Research and Policy (CIDRAP) calculated that this outbreak will likely last up to 24 months (1). In 307 This article is freely accessible online.

Prognostic factors for mortality, ICU and hospital admission due to SARS-CoV-2: A systematic review and meta-analysis of cohort studies in Europe

“…As per our inclusion criteria, all cohort studies were based in Europe and included 23 studies from Spain (14, 16, 17, 22, 28, 29, 32, 33, 35, 50, 54, 57-59, 64, 67, 70, 80, 89, 92, 96, 97, 101), 22 studies from Italy (13,19,21,23,25,30,38,39,45,47,48,55,56,61,62,68,71,77,79,90,91,93), 15 studies from France (20,24,27,31,40,41,43,53,60,63,65,74,76,86,99), ten studies from the UK (26,34,44,49,52,66,72,75,87,98), four included patients from more than one country (69,…”

“…As per our inclusion criteria, all cohort studies were based in Europe and included 23 studies from Spain (14, 16, 17, 22, 28, 29, 32, 33, 35, 50, 54, 57-59, 64, 67, 70, 80, 89, 92, 96, 97, 101), 22 studies from Italy(13, 19, 21, 23, 25, 30, 38, 39, 45, 47, 48, 55, 56, 61, 62, 68, 71, 77, 79, 90, 91, 93), 15 studies from France (20, 24, 27, 31, 40, 41, 43, 53, 60, 63, 65, 74, 76, 86, 99), ten studies from the UK (26, 34, 44, 49, 52, 66, 72, 75, 87, 98), four included patients from more than one country (69, 73, 88, 94), three from Germany (46, 51, 78), two studies from Sweden(36, 100), two from Denmark (42, 83) and one study from Belgium (81), Finland (5), the Netherlands (18), Norway (85) and Poland (37). The diagnosis of COVID-19 was made mainly with a PCR test, except for in five studies in which the diagnosis was made with the ICD Classification (20, 24, <...>…”

Unusual Presentation of a Post-procedural Breast Hematoma: A Case Report

“…Moreover, due to the first admission in the COVID-19 section, the patient required 14 days quarantine and further COVID-19 swab test at home, impacting on patient's return to daily activities and work. Additionally, due to the cross-infection risk, all health care workers wore personal protective equipment (PPE) to reduce cross infection in oncological frail patients (36,37).…”

COVID-19 and Malignancy: Exploration of the possible genetic and epigenetic interlinks and overview of the vaccination scenario

“…The study presided over by Vanni et al [69] tried to understand more about the prognostic value of blood tests in a small cohort of 97 Italian cancer patients suffering from SARS-CoV-2 infection where the cohort was divided into 2 groups [moderate, severe]. Despite the reported lower lymphocyte count in severe group, it was proved to be statistically insignificant.…”

“…In the study at MSK center [10] , Elevated initial creatinine was associated with increased severity (P=0.002 for ICU/intubation/DNI; P=0.002 for death) [10] . From these studies, it can be inferred that to provide better treatments, previous oncological history should be taken into consideration in times of admitting such patients in the hospitals [69] .…”